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ABSTRACT
Uncontrolled cell proliferation and cytoskeletal
remodeling are responsible for tumor development
and ultimately metastasis. A number of studies have
implicated microRNAs in the regulation of cancer cell
invasion and migration. Here, we show that miR-23b
regulates focal adhesion, cell spreading, cell-cell
junctions and the formation of lamellipodia in breast
cancer (BC), implicating a central role for it in cyto-
skeletal dynamics. Inhibition of miR-23b, using a
specific sponge construct, leads to an increase of
cell migration and metastatic spread in vivo,
indicating it as a metastatic suppressor microRNA.
Clinically, low miR-23b expression correlates with
the development of metastases in BC patients.
Mechanistically, miR-23b is able to directly inhibit a
number of genes implicated in cytoskeletal remodel-
ing in BC cells. Through intracellular signal transduc-
tion, growth factors activate the transcription factor
AP-1, and we show that this in turn reduces miR-23b
levels by direct binding to its promoter, releasing the
pro-invasive genes from translational inhibition. In ag-
gregate, miR-23b expression invokes a sophisticated
interaction network that co-ordinates a wide range of
cellular responses required to alter the cytoskeleton
during cancer cell motility.
INTRODUCTION
Deregulation of cell cycle progression genes is crucial to
tumor growth, and additional genetic modiﬁcations are
required to promote motile and invasive behaviors in
cancer cells, leading to tumor dissemination and
metastasis.
The cytoskeleton controls cell motility, invasion and
adhesion. Three members of the Rho family of small
GTPases, RhoA, Rac1 and cell division cycle 42, are
crucial in regulating the molecular pathways implicated
in cell migration (1,2), controlling cytoskeletal dynamics,
cell adhesion, morphology and motility (1). This is
achieved via effector proteins that regulate actin-based
structures, and the p21-activated kinases (PAKs) are
among the best characterized effectors of cell division
cycle 42 and Rac1 (3). In addition, several growth factor
receptor tyrosine kinases activate PAKs through Rho
GTPases leading to cytoskeletal remodeling (4–6).
Furthermore, in breast cancer (BC), the HER-2 pathway
is able to regulate the actin cytoskeleton and cell motility
via PAK1 and PAK2 activation and distinct downstream
signaling mechanisms (7).
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MicroRNAs (miRNAs) are small, single-stranded
RNAs that regulate gene expression (8), and their
dysregulation can therefore contribute to cell motility
and metastasis by affecting relevant transcripts (9–13).
Using a bioinformatic approach, we identiﬁed miR-23b
as a miRNA implicated in cytoskeletal remodeling and
motility, and we further demonstrated this ﬁnding
through a number of experimental techniques. In
addition, using RNA-sequencing (RNA-seq) and
luciferase reporter assays, we validated a subset of cyto-
skeletal genes as direct targets of miR-23b in BC,
implicating a direct role of this miRNA in cytoskeletal re-
modeling and motility. Notably, when AP-1 is activated by
growth factors, it binds directly to the miR-23b promoter,
thereby reducing its expression, which indicates that this
event contributes to motility and metastasis in BC.
MATERIALS AND METHODS
Cell culture
BC cell lines (MCF-7, MDA-MB-231 and MDA-MB-468)
and colon cancer HCT116 cell lines were maintained in
Dulbecco’s modiﬁed Eagle’s medium and McCoy’s
medium, respectively, supplemented with 10% FCS, 1%
penicillin/streptomycin and 2% glutamine. MDA-MB-231
cells isolated from distant sites were maintained as previ-
ously described (14). Stable transfected MDA-MB-231 cell
clones were expanded in G-418 (Roche Applied Science,
Burgess Hill, UK).
Plasmid constructions
The miR-23b sponges were constructed by annealing, pur-
ifying and cloning oligonucleotides containing six tandem
bulged miRNA binding motifs, into the HindIII and
BamHI sites of the pEGFP-C1 plasmid (Contech, Saint-
Germain-en-Laye, France), as 30UTR of the EGFP
mRNA. For 30UTRs reporter construction, the 30UTR
of Pak2 or Pak1 were PCR-ampliﬁed from human
genomic DNA and cloned into the pMIR-REPORT
Fireﬂy Luciferase vector. The miR-23b sensors were con-
structed as for miR-23b sponges, but into the SpeI and
HindIII sites of the pMIR-REPORT Fireﬂy Luciferase
vector. The ANXA2, ARHGEF6, CFL2, LIMK2,
PIK3R3, PLAU and TLN2 30UTRs cloned into
pLightSwitch_30UTR GoClone vectors were used
(Switch Gear Genomics, Menlo Park CA, USA). The
indicated mutagenized miR-23b seed-containing luciferase
reporter vector was created with a QuickChange II or II
XL Site-Directed Mutagenesis Kit (Agilent Technology,
Edinburgh, UK) according to the manufacturer’s instruc-
tions. All plasmid sequences were veriﬁed to be free of
mutations by direct sequencing. The sequences of all
primers used for plasmid construction and site-directed
mutagenesis are reported in Supplementary Table S1.
Transfections, reporter assays and cell treatments
Cells were plated in 6-well plates at 50% conﬂuence and
transfected with either the miRNA mimics (5 nM),
miRNA inhibitors (100 nM) (Applied Biosystems,
Warrington, UK) or siRNA oligonucleotides (40 nM)
for 48 h using HiPerFect Transfection Reagent (Qiagen,
Crawley, UK). For experiments of miRNA over-expres-
sion for 9 days, cells were plated in 6-well plates at 30%
conﬂuence and transfected with the miRNA mimics
(5 nM); after 72 h of transfection, cells were split and
re-transfected with additional miRNAs mimics; this
protocol was repeated every 3 days for up to 9 days.
Transfection of GFP-sponge-expressing plasmids was per-
formed using Lipofectamine 2000 (Life Technologies Ltd,
Paisley, UK). For 30UTR reporter assays, cells were co-
transfected with Renilla Luciferase vector, the indicated
miRNA precursors or plasmids and 30UTR-p-MIR
REPORT Fireﬂy Luciferase vectors in 24-well plates and
analyzed as previously described (15). Cells co-transfected
with pLightSwitch_3UTR GoClone vectors, and the
indicated miRNA precursors or plasmids in 24 well
plates were lysed using a passive lysis buffer (Promega,
Southampton, UK) and processed with the LightSwitch
Assay System (Switchgear Genomics Menlo Park CA,
USA) according to manufacturer’s instructions.
Luciferase activity detection was performed using a
GLOMAX 96 Microplate luminometer (Promega). For
EGF treatment, MDA-MB-468 cells were plated in tripli-
cate in normal growth medium. After 24 h, EGF
(25 ng/ml) was added for the indicated time points in
three independent biological replicates.
Immunoﬂuorescence and cell–cell junction quantiﬁcation
Cells were ﬁxed with 4% paraformaldehyde and
permeabilized in 0.2% Triton-X-100 for 30min. F-actin
was detected with phalloidin-Alexa Fluor 488
(Invitrogen), and nuclei were visualized with TO-PRO-3
(Invitrogen). For E-cadherin and focal adhesion (FA)
visualization, cells were stained either with anti-
E-cadherin antibody (HECD-1) (M106, Takara Bio Inc.)
or anti-Vinculin antibody (V9264, Sigma-Aldrich) and
imaged using a confocal microscope. To analyze cell–cell
junction linearity, the junction lenghts and distances
between vertices were manually traced and measured by
using LSM 5 Image Browser (Carl Zeiss MicroImaging,
Inc.). To highlight the area of FAs, the images taken were
inverted in black-and-white color and analyzed using NHI
ImageJ software for FA area quantiﬁcation. To study
-lamellipodial formation, cells were imaged using
ImageXpress Micro microscope (Molecular Devices),
and lamellipodia number was manually counted in a
blind fashion (100 cells per each condition in the three
independent experiments).
In vitro migration and invasion assays
For cell-tracking assays, cells were seeded in 24-well tissue
culture plates at a ﬁnal density of 1 104. After 48 h of
transfection, time-lapse sequences were digitally recorded
at intervals of 20min for 24 h using the ImageXpress
Micro microscope (Molecular Devices). Cell trajectories
were determined by following the centroid of the nuclei
using the ImageJ plugin ‘MTrackJ’ (http://www.
imagescience.org/meijering/software/mtrackj/), and speed
of cell body movement was calculated for mean cell
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migratory speed. A 50–100 cells per each condition were
analyzed, and three independent experiments were per-
formed. For transwell migration assays, 5 104 cells
were seeded atop uncoated membranes with 8.0 mm
pores (BD Biosciences). Cell were plated in serum free-
medium and allowed to migrate toward a complete
growth medium for 9 h. For 3D Collagen-I invasion
assays, 7 104 cells were plated in black-walled 96-well
plates and allowed to attach. Collagen-I gels (n=5 gels
per condition, 100 ml) were prepared as described (16) at a
ﬁnal concentration of 2.3mg/ml and added atop the cells.
After polymerization and equilibration for 1 h at 37C and
5% CO2, collagen gels were coated with 100 ml of cell
culture medium supplemented with 10% FCS as chemo-
attractant, and cell invasion was allowed for 16–24 h.
Collagen gels containing invaded cells were then ﬁxed
and stained, and z sections were taken by confocal micros-
copy. Invasion indexes were calculated as the number of
cells at 40 mm divided by those at 0 mm. Three independent
experiments were performed.
Cell growth and Annexin V-apoptotic assays
MCF7 and MDA-MB-231 cells growth was analyzed by
performing an SRB assay. Cells were seeded in 96-well
plates and transfected with the indicated molecules. The
SRB cell viability assay was performed 48 h after transfec-
tions as described previously (17). To assay the apoptotic
properties of miR-23b, MDA-MB-231 were transfected
with the indicated microRNA precursor mimics and the
cell death control siRNAs (20 nM) (Qiagen) used as
positive control. After 48 h, detached cells were
combined with adherent cells after lifting with trypsin-
EDTA, stained with Annexin V/PE apoptosis detection
kit (BD Biosciences) according to manufacturer’s
protocol and analyzed using a FACSCanto II ﬂow
citometer (BD Biosciences). Apoptotic cells were repre-
sented by high PE-Annexin V ﬂuorescence signals.
Spreading assays
Spreading assays was performed as previously
described (18).
Patients and samples
To investigate the potential role of miR-23b in BC metas-
tasis, we prospectively measured their expression in
primary BCs and corresponding lymph node metastasis
from patients with lymph node positive BC. Between
January 2008 and February 2010, we obtained primary
breast tumors and corresponding lymph node metastases
from 66 consecutive individuals eligible for chemotherapy
at Imperial College Healthcare NHS Trust, London, UK.
All 132 samples were formalin-ﬁxed and parafﬁn-
embedded. The clinico-pathologic characteristics are
listed in Supplementary Table S2. Prospective written
consent was obtained in accordance with ethical
guidelines.
Statistical analysis
Data are presented as mean±standard error of the mean
calculated using Graph Prism software. Student’s t-test
and Chi-Square test were used for comparison, with
P< 0.05 considered signiﬁcant.
Sequence data were submitted to Gene Expression
Omnibus database, accession number GSE37918.
RESULTS
Bioinformatic analyses reveal that miR-23b is involved in
cytoskeletal remodeling and adhesion
Using a bioinformatic approach and an extensive litera-
ture review, we identiﬁed candidate miRNAs involved in
cell motility and invasion. We selected miR-23b, as it
reduces hepatocellular and cervical cancer cell motility
through the regulation of PLAU and c-Met (19) and
reduces experimental metastasis formation in colorectal
cancer (20). However, its role in BC and the subsequent
pathways regulated remain largely unknown. Nine
hundred and thirty-eight randomly chosen genes and 938
potential miR-23b targets [identiﬁed using TargetScan
(21)] were analyzed using DAVID (http://david.abcc.
ncifcrf.gov/home.jsp) for gene ontology (GO) annotation
and pathway enrichment analysis (22,23). This method
suggested that miR-23b may regulate pathways involved
in cancer, cytoskeletal remodeling, cell-cell junctions and
cell adhesion (Supplementary Figure S1).
The miR-23b expression in cancer cell lines enhances
cell–cell adhesion
We transfected epithelial-like (MCF-7) and mesenchymal-
like (MDA-MB-231) BC cells with synthetic miR-23b pre-
cursor or a negative control (miR-n.c.). Ectopic expression
of miR-23b increased epithelial characteristics in MCF-7
cells, as demonstrated by tighter colony morphology with
marked cell–cell junctions (Figure 1A), independent of
E-cadherin (CDH1) expression (Figure 1B). However, as
miR-23b over-expression did not induce these characteris-
tics in mesenchymal-like MDA-MB-231 cells (Figure 1C),
and in addition, CDH1 expression did not change upon
miR-23b over-expression, we hypothesized that
such effects were unlikely to be due to re-expression of
adhesion molecules during the mesenchymal-to-epithelial
transition, but more likely due to miR-23b affecting the
tension of existing cell–cell adhesions.
Next, we aimed to induce mesenchymal-to-epithelial
transition via prolonged (9 days) miR-23b over-expres-
sion, using immunoﬂuorescence to examine CDH1 and
cell junction formation (24) (Figure 1D and E). The
miR-23b over-expressing-MCF-7, but not MDA-MB-231
cells, overall showed more orderly and stable tight and
adherens junctions compared with controls, conﬁrming
that miR-23b leads to an enhanced tension between
existing cell–cell junctions (Figure 1D and E). The quan-
tiﬁcation of this effect is expressed as a linearity index,
deﬁned by the ratio of junction length to the distance
between vertices (25), and supported that junctions in
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miR-23b-expressing MCF-7 cells were straighter
compared with controls (Figure 1F).
The miR-23b expression increases FA size and cell
spreading and modulates the formation of lamellipodia
We stained MDA-MB-231 cells for the FA marker
vinculin (26) to assess the effect of miR-23b
over-expression on their ability to form FAs. FAs were
signiﬁcantly larger in cells after over-expressing miR-23b
compared with miR-n.c.-transfected controls (Figure 1G).
Remarkably, we also noticed that the number of cells
forming lamellipodia was signiﬁcantly less after miR-23b
over-expression and at most these formed only small
narrow protrusions (Figure 1H).
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Figure 1. miR-23b expression affects cytoskeletal remodeling as predicted by bioinformatic analyses. (A) Phase-contrast images of MCF-7 cells upon
transfection with miR-23b and miR-n.c. precursors (5 nM) for 48 h. (B) Western blot showing E-cadherin and b-actin expression in MCF-7 cells
transfected with miR-23b and miR-n.c. precursors (5 nM) for 48 h. b-actin was used as a loading control. (C) Phase-contrast images of MDA-MB-
231 cells upon transfection with miR-23b and miR-n.c. precursors (5 nM) for 48 h. (D) From left to right: TO-PRO-3 staining of DNA,
immunoﬂuorescence staining of E-cadherin (1:1000), Alexa Fluor 488 phalloidin (1:500) staining of F-actin and overlay of the three images of
MCF-7 cells transfected with miR-23b and miR-n.c. precursors (5 nM) for 9 days. Scale bar=20 mm (E) From right to left: TO-PRO-3 staining
of nuclei, immunoﬂuorescence staining of E-cadherin (1:1000), Alexa Fluor 488 phalloidin (1:500) staining of F-actin and overlay of the three images
of MDA-MB-231 cells transfected with miR-23b and miR-n.c. precursors (5 nM) for 9 days. Scale bar=20 mm. (F) Quantiﬁcation of junction
linearity. Junction length (green) and distance between vertices (pink) were measured and a linearity index was calculated by dividing the two
measures (right). This index decreases in miR-23b over-expressing MCF-7 cells. Scale bar=20 mm. 150–250 junctions per condition in two
independent experiments were counted. Data are mean±s.e.m. (P=0.0001, Student’s t-test). (G) Immunoﬂuorescence staining of MDA-MB-231
using Vinculin antibody (1:400); images were false colored in a black-and-white fashion to highlight FAs. After transfection with miR-23b and miR-
n.c. precursors (5 nM) for 48 h the cells were left to adhere on coverslips coated with 50 uM of collagen I for 1 h before staining. Scale bar=10 mm.
The bottom graph shows the FA size per treated cell. Quantiﬁcation of FA size is represented as the average of FA area per cell. Data are shown as
mean values± s.e.m. from three independent experiments (P=0.04, Student’s t-test). (H) Phase-contrast images of MDA-MB-231 cells transfected
with the indicated miRNA precursors (5 nM) for 48 h. Lamellipodial structures are indicated by continuous arrows; lack of lamellipodia is indicated
by discontinuous arrows. The box plot on the right shows the number of lamellipodia formed after treating the cells with the indicated precursors.
Scale bar=100 mm. 50–150 cells per condition in three independent experiments were counted. Data are mean±s.e.m. (P=0.0003, Student’s t-test).
The image at the bottom shows typical lamellipodia in MDA-MB-231 cells transfected with the indicated precursors (5 nM) for 48 h and stained with
Alexa Fluor 488 phalloidin.
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To assess the effects of miR-23b on cell-spreading
capacity, we plated MDA-MB-231 cells for 30, 60 and
120min (Figure 2) on Type I collagen. The miR-23b-
transfected cells spread more than controls and after
30min contained lamellar protrusions, stress ﬁber-like
actin bundles and punctate peripheral FAs, whereas the
controls remained rounded with no FAs or F-actin
bundles (Figure 2).
The miR-23b regulates breast cancer cell motility
and invasion
We found that miR-23b over-expression did not affect the
proliferation rate or promote apoptosis in cultured MDA-
MB-231 or MCF-7 cells (Supplementary Figure S2A
and B). However, miR-23b transfection markedly
reduced in vitro migration of highly motile MDA-MB-
231 cells compared with miR-n.c., effects which were
similar to those seen in miR-31 over-expressing positive
controls (Figure 3A). The miR-31 reduces MDA-MB-231
cell motility and experimental metastasis in BC (13) and
accordingly miR-23b and miR-31 both reduced cell
migratory speed (Figure 3B and Supplementary Movies
S1–S3) and shortened migration trajectory lines
(Figure 3C). Next, we developed MDA-MB-231 cell
lines that stably expressed an EGFP-miR-23b sponge con-
struct (Supplementary Figure S3A), enabling them to
inhibit endogenous miR-23b. In particular, clone 10
reduced miR-23b levels by up to 70% (Supplementary
Figure S3B). Co-expression of the sponge vector and a
sensor vector [that contains six perfectly interacting sites
for miR-23b (Supplementary Figure S3D)] increases
luciferase activity compared with empty vector control
(Supplementary Figure S3E), demonstrating the efﬁciency
of the sponge vector in the inhibition of miR-23b activity.
Notably, the inhibition of miR-23b signiﬁcantly
increased MDA-MB-231 cell migration (Figure 3D) and
increased lamellipodia size (Supplementary Figure S3C),
which was consistent with the effects of miR-23b over-
expression on lamellipodia as described earlier in the
text (Figure).
To evaluate invasive capacity, we tested MDA-MB-231
migration in 3D matrices. The miR-23b over-expression
and silencing signiﬁcantly reduced and increased cell
invasion, respectively (Figure 3E and F).
The miR-23b directly targets PAK2 and increases myosin
light chain II phosphorylation
We implicated miR-23b in cytoskeletal regulation and
selected PAK2 as its candidate target based on our
TargetScan analysis (Figure 4A and Supplementary
Figure S4A) and its previously described role in cytoskel-
etal remodeling (7,27). Subsequently, we found that
silencing PAK2 reduced motility and increased myosin
light chain (MLC) II phosphorylation in MDA-MB-231
cells (Supplementary Figure S4C and D). Interestingly,
PAK3 was not detected in three epithelial cancer cell
lines (data not shown), consistent with its restricted
tissue expression pattern (28). The miR-23b speciﬁcally
reduced PAK2 levels in all tested cell lines, but not
PAK1 (which is not a predicted miR-23b target; Figure
4B and Supplementary Figure S4B). Accordingly, MLC II
phosphorylation was upregulated on miR-23b over-ex-
pression, which is important for regulating cytoskeletal
reorganization and cell migration (Figure 4C).
Furthermore, PAK2 levels increased in MCF-7 cells tran-
siently transfected with miR-23b sponge construct and in
MDA-MB-231 stably transfected with miR-23b sponge
construct (i.e. after reduction of endogenous miR-23b
levels; Figure 4D and Supplementary Figure S4E).
Luciferase reporter assays next demonstrated that miR-
23b regulates PAK2, but not PAK1, by direct interaction
with its 30UTR (Supplementary Figure S4F–I).
AP-1 directly interacts with the miR-23b promoter and
transcriptionally suppresses its expression
The transcription factor AP-1 is activated through
EGFR and HER-2 signaling pathways. It subsequently
recognizes TPA-responsive elements (TREs) in promoter
and enhancer regions of target genes involved in cell
motility and growth (29) and is composed of c-JUN
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and c-FOS heterodimers (Supplementary Figure S5A)
(30). Analysis of the transcription unit (TU) for tran-
scription factors that may regulate this miRNA gene,
revealed conserved and less conserved TREs along
miR-23b TU (Figure 5A). The miR-23b is encoded in
the complex TU, Chromosome 9 open reading frame 3
(C9orf3; Figure 5A), and c-MYC regulates its expression
by directly interacting with its upstream transcriptional
start site (31,32).
To determine whether AP-1 regulates miR-23b tran-
scription, we next silenced c-FOS and c-JUN in
MDA-MB-231 cells. Although individual gene silencing
had little effect, co-silencing of both genes signiﬁcantly
increased primary (pri-) and mature miR-23b levels, thus
implicating AP-1 in the regulation and reduction of miR-
23b expression (Figure 5B and Supplementary Figure
S5B). In addition, c-JUN-c-FOS co-silencing reduced
PAK2 levels and greatly increased MLC II phosphoryl-
ation (Supplementary Figure S5C). Next, chromatin
immunoprecipitation revealed that AP-1 is directly
involved in the transcriptional inhibition of miR-23b, as
c-JUN directly bound to at least two evolutionarily
miR-23b miR-31 miR-n.c.
0
50
100
150
200
M
ig
ra
to
ry
 ce
lls
pe
r 
fie
ld
miR-23b miR-n.c.miR-31
A
B
P = 0.004
P = 0.001
C
Sp
ee
d 
[μ
m
/s
]
E
In
va
si
on
 in
de
x
Sponge-23b Vector
P = 0.0073
P = 0.0055
0
0.2
0.4
0.6
0.8
1
1.2
miR-23b miR-n.c.
P = 0.001 F
In
va
si
on
 in
de
x
0
0.5
1
1.5
2
2.5
3
3.5
4
Sponge-23b Vector
P = 0.04
M
ig
ra
to
ry
 c
el
ls
pe
r 
ﬁe
ld
miR-23b miR-n.c.miR-31
D
Sponge-23b Vector
P < 0.0001
miR-23b miR-31 miR-n.c.
0.000
0.005
0.010
0.015
0.020
0.025 400
300
200
100
0
Figure 3. mir-23b inhibits MDA-MB-231 cell motility and invasion. (A) Transwell migration assays were performed for 9 h after transfecting
MDA-MB-231 cells with the indicated precursors (5 nM) for 48 h. The graph on the right indicates cell migration expressed as percentage of the
average of migratory cells per ﬁeld (n=5 ﬁelds per transfection). Data are mean of three experiments± s.e.m. performed in triplicates (P=0.004,
P=0.001, Student’s t-test). (B) Motility of MDA-MB-231 cells expressing the indicated precursors was examined for 24 h by phase-contrast, time-
lapse microscopy. Cell speed of 50–100 cells per condition was quantiﬁed and speed averages are presented as mean of three experiments± s.e.m.
(P=0.0001, Student’s t-test). (C) Plots show overlays of representative trajectories described by pre-miR-expressing MDA-MB-231 cells during time-
lapse motility assays. (D) Transwell migration assays of MDA-MB-231 cells stably expressing the indicated constructs (Vector refers to pEGFP-C1
empty vector) were performed for 9 h. The graph on the right indicates cell migration expressed as a percentage of the average of migratory cells per
ﬁeld (n=5 ﬁelds per transfection). Data are mean of three experiments± s.e.m. performed in triplicates (P< 0.0001 Student’s t-test). (E) Invasion of
MDA-MB-231 cells transfected with miR-23b and miR-n.c. precursors (5 nM) for 48 h was assessed in collagen-I-3D-matrices (2.3mg/ml) for 16 h.
Confocal z sections were collected from each well at 0 mm (bottom of the well) and 40 mm and invasion indexes were calculated as the number of cells
at 40 mm divided by those at 0 mm. Invasion indexes are mean of three experiments± s.e.m. performed in quintuplicates (P=0.001 Student’s t-test).
(F) Invasion assays using MDA-MB-231 cells stably expressing the miR-23b-sponge construct or the parental control pEGFP-C1 plasmid vector
were performed as in (E). Invasion indexes are mean of three experiments± s.e.m. performed in quintuplicates (P=0.04, Student’s t-test).
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conserved TREs in the TU of C9orf3 (Figure 5A and C).
c-JUN also bound to the IL-6 gene promoter, used as
positive control (33), but not a genomic DNA region
that lacks the TREs (Figure 5C).
As c-JUN is transcriptionally activated by EGF (34), we
exposed EGFR positive MDA-MB-468 BC cells to
EGF. We found that c-Jun mRNA increased
within 20 min and for up to 2 h (Supplementary Figure
S5D), as expected (34), whereas miR-23b levels concomi-
tantly decreased (Supplementary Figure S5E), thus
indicating that EGF reduces miR-23b expression
through c-JUN.
The action of miR-23b on the cytoskeleton is mediated by
regulation of a subset of cytoskeletal genes
By treating BC cells with a siRNA against PAK2, we
obtained 94% silencing of the gene (Supplementary
Figure S4D). On the other hand, we showed that
miR-23b treatment reduced PAK2 levels to 60%
(Figure 4B). As miR-23b induced a stronger reduction
of MDA-MB-231 motility compared with the silencing
of PAK2 alone (Figure 3B and Supplementary Figure
S4C), this miRNA must also mediate this effect through
the regulation of other cytoskeletal genes. With this hy-
pothesis in mind, we performed RNA-seq of miR-23b-
over-expressing MCF-7 cells and MDA-MB-231 cells
stably transfected with miR-23b sponge vector. The
miR-23b expression in MCF-7 cells affected levels of
7.4% of transcripts, whereas in MDA-MB-231 cells
stably transfected with the sponge vector, gene expression
changed for 22.9% (Supplementary Table S3). As
miRNAs repress gene expression, we selected
downregulated genes from miR-23b-over-expressing
MCF-7 and upregulated genes from miR-23b-sponge
MDA-MB-231 (Supplementary Table S4) and performed
GO term enrichment analysis (Supplementary Figure S6).
Consistent with our ﬁndings, we observed enrichment in
cytoskeletal organization genes in both cases
(Supplementary Figure S6A and B). To further evaluate
miR-23b targets, we intersected genes downregulated in
MCF-7 cells over-expressing miR-23b with those genes
upregulated in MDA-MB-231 cells containing sponge
vectors that stably reduce miR-23b and combined them
with those genes derived from a TargetScan analysis
(Supplementary Table S4). We reasoned that the intersec-
tion would contain a highly enriched list of direct targets
and considered a cutoff expression change of 1.2-fold
sufﬁcient, as miRNAs regulate transcripts by promoting
destabilization through deadenylation (35,36), although
mediating a stronger effect on protein translation (37).
Higher fold changes may result in omitting many
relevant targets. Furthermore, the impact of miRNAs on
gene targets is variable and usually mild (38,39). Seventy
percent of previously described miR-23b gene targets were
among the intersection representing those genes
downregulated in MCF-7 and/or upregulated in MDA-
MB-231 and those in the TargetScan list (Supplementary
Tables S4). Accordingly, we found that PAK2 is within
this intersection (Supplementary Table S4). From this
gene list, we selected a group of pro-metastatic genes for
further validation.
Cytoskeletal genes are direct targets of miR-23b in BC
This ﬁnding was further validated performing RT-qPCR
on 15 pro-metastatic genes involved in cytoskeletal re-
modeling from our RNA-seq analysis, that contain
‘seeds’ for miR-23b interaction (TargetScan analysis).
Accordingly, these were all found to be downregulated
in MCF-7 over-expressing miR-23b and upregulated in
MDA-MB-231 stably transfected with miR-23b sponge
vector (Supplementary Figure S7). Next, we selected
seven genes (LIMK2, ARHGEF6, CFL2, PIK3R3,
PLAU, ANXA2, TLN2) that are well described in the
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II phosphorylation. (A) Predicted duplex formation between human
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literature as promoters of cell motility through regulation
of cytoskeletal remodeling pathways (19,40–43) and per-
formed 30UTR luciferase reporter assays (Figure 6). We
could demonstrate the direct regulation by miR-23b of six
of seven of these using both over-expression and inhibition
of miR-23b (Figure 6A and C). In addition, site-directed
mutagenesis precisely deﬁned the sites of miR-23b inter-
action within their 30UTRs (Figure 6A and B).
The miR-23b expression is inversely correlated with breast
cancer metastases
We hypothesized that loss of miR-23b may be involved in
BC spread and therefore examined miR-23b levels in
MDA-MB-231 cells that had been inoculated into the
mammary fat pads of nude mice and allowed to form
metastatic deposits (44,45). We found higher miR-23b
levels in the primary tumor cells at the inoculated sites,
compared with metastatic cells at distant sites, such as
the adrenal glands, bones and lungs (Figure 7A).
Subsequently, we measured miR-23b levels in a small
number of paired primary and metastatic BC patient
samples. Accordingly, miR-23b levels were higher in
primary tumors, compared with their corresponding
lymph-node metastases (Figure 7B). We next validated
this in a larger patient cohort (n=132; 66 primary
tumors and matching metastases) and again conﬁrmed
signiﬁcantly higher mean expression of miR-23b in
primary tumors than in the metastases (Figure 7C).
The miR-23b inhibition increases experimental metastasis
and tumor growth in vivo
We further investigated the role of miR-23b in an experi-
mental metastasis model. We injected MDA-MB-231 cells,
stably transfected with miR-23b sponge or empty vector
control constructs, into the mammary fat pad of BALB/c
Nude mice and allowed tumor growth up to 300mm2
(n=7 per treatment). We observed that local tumor
invasion into the surrounding fat was dramatically
increased by long-term miR-23b inhibition (Figure 8A).
Extensive metastatic deposits were only detected in
draining lymph nodes of mice injected with stably trans-
fected miR-23b sponge cells, indicating that reduced miR-
23b activity enhanced the ability of these cells to spontan-
eously metastasize (Figure 8B). Our in vitro ﬁndings
showed that neither expression (Supplementary Figure
S2A) nor inhibition of miR-23b (Supplementary Figure
S8A) signiﬁcantly altered cell growth, but miR-23b inhib-
ition surprisingly increased tumor growth in vivo
(Figure 7C). Normally, xenografts derived from MDA-
MB-231 injection into the mammary fat pad of immuno-
compromised mice have extensive central necrotic areas
(46); however, we saw that miR-23b downregulation dra-
matically reduced tumor necrosis without signiﬁcantly af-
fecting the number of tumor microvessels (Figure 8D and
Supplementary Figure S8B). This could explain the
discrepancies seen in cell growth rate in vivo and in vitro
following miR-23b inhibition.
DISCUSSION
The current study focused on miR-23b because, although
its involvement in some cancers is well-known, its global
functions and role in BC are poorly deﬁned. Using a
pathway enriched analysis, we have suggested a role for
miR-23b in cytoskeletal remodeling. We subsequently
demonstrated this experimentally and validated a group
of cytoskeletal genes as its direct targets.
The miR-23b over-expression increased epithelial char-
acteristics in MCF-7 cells, but not in mesenchymal-like
cells where CDH1 is not expressed. This is probably
because miR-23b was unable to promote the formation
of new junctions or increase CDH1 levels (Figure 1B),
but rather enhanced the tension of existing ones. CDH1
is the principal mediator of adherens junction formation
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Figure 7. mir-23b expression is inversely correlated with metastasis. (A)
RT-qPCR shows relative expression levels of miR-23b in MDA-MD-
231 breast cancer cell lines that formed the primary tumor at the
inoculation site (TMD-231) and cells that metastasized to the adrenal
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between cells and although intracellular it is anchored to
the actin cytoskeleton through a- and b-catenin (47).
Recently, Zhang et al. (20) reported that miR-23b can
inhibit migration and metastasis in colorectal cancer
cells, indicating a similar role may exist for it in other
tumor types. They showed that miR-23b increases epithe-
lial characteristics through the upregulation of CDH1
(20). However, we could not demonstrate CDH1 upregu-
lation on over-expression of miR-23b, neither at the RNA
nor the protein level. This indicates that miR-23b
probably confers epithelial characteristics in both tissues
types by different pathways. Importantly, our RNA-seq
analysis showed that miR-23b over-expression increased
the expression of the cell–cell adhesion molecule Nectin1,
which probably contributes to the formation of adherens
junctions, as its downregulation in MCF-7 cells mediates
EMT (48). In adition, LMO7 is involved in the association
between CDH1 and Nectin1 at the cell–cell junction level
(49) and was upregulated by miR-23b expression
(Supplementary Table S3).
The HER family of tyrosine kinase receptors is fre-
quently over-expressed in breast and other types of
cancers. Ligands such as EGF and heregulin can bind to
them and increase the metastatic potential of cancer cells
(50). AP-1 is a transcription factor formed by the inter-
action between c-FOS and c-JUN that is activated by
HER-2 signaling and increases metastasis by regulating
pro-metastatic genes (51). Here, we show that miR-23b
is a miRNA transcriptionally suppressed by AP-1
(Figures 5 and 9). On the other hand, EGFR stimulation
by EGF decreased the levels of mature miR-23b
(Supplementary Figure S5 and Figure 9). The over-expres-
sion of miR-23b consequently regulates cytoskeletal
dynamics and decreases cell motility and invasion
in vitro. These results are consistent with the strong
down-regulation of cell motility exerted by miR-23b
over-expression in MCF-7 cells, recently shown by
Zhang et al (20). This indicates that its downregulation
by AP-1 is an important event that then leads to the ac-
quisition of a more invasive phenotype for the cancer cells.
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Figure 8. miR-23b inhibition increases tumor growth by reducing cell necrosis and increasing local invasion in vivo. (A) H&E stain of GFP-miR-23b-
Sponge expressing- or GFP expressing-MDA-MB-231 cell primary tumors 2 months after orthotopic injection. Black arrows indicate regions of
invasion into the surrounding fat. (B) Representation of a lymph node from a mouse injected with GFP-miR-23b-Sponge expressing-MDA-MB-231
cells H&E stained. The black arrow indicates metastatic areas whereas green arrows indicate residual normal tissue characterized by the presence of
smaller nuclei (n=7 per treatment). A quantiﬁcation of the tissue type within the lymph nodes is shown in the graph on the right (P=0.0001, Chi-
Square test). (C) Line chart showing changes in tumor volume (mm3) over time (weeks) after injection of 1 106 GFP-miR-23b-Sponge expressing-
or GFP expressing-MDA-MB-231 cells into the mammary fat pad of BALB/c nude mice (n=7 per treatment). (D) H&E stain of MDA-MB-231 cell
primary tumors 2 months after orthotopic injection. Arrow indicates region of necrosis (n=7 per treatment). The graph below shows a
quantiﬁcation of necrosis expressed as percentage of necrotic areas formed within the primary tumors (P=0.002, Student’s t-test).
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Importantly, miR-23b is part of a cluster composed of
miR-23b, miR-27b and miR-24-1 that are transcribed as
a unique primary transcript (52). This may indicate that
AP-1 mediates its effect by regulating all of the miRNA
components of this cluster, but this observation requires
further investigation.
Furthermore, the inhibition of miR-23b, by stably
transfecting BC cells with a miR-23b sponge construct
(i.e. loss-of-function), increases spontaneous metastasis
in the lymph nodes of orthotopically injected nude mice.
This demonstrated that the downregulation of miR-23b is
an important event that mediates metastatic formation
in vivo. Notably, miR-23b levels are reduced in MDA-
MB-231 cells that have metastasized to distant organs
(e.g. adrenal glands, bones and lungs; Figure 7A) after
creation of orthotopic BC xenografts in nude mice.
More importantly, we found miR-23b expression is signiﬁ-
cantly downregulated in lymph node metastases in a large
patient cohort of paired BC samples (Figure 7B and C).
GO terms analysis of our RNA-seq data, obtained after
miR-23b perturbation in BC cells, demonstrated that this
miRNA regulates pathways involved in cytoskeletal re-
modeling, which is an essential mechanism that modiﬁes
tumor cells giving them more motile characteristics during
the metastatic process. Accordingly, we showed here that
miR-23b inhibits a large number of cytoskeletal genes, of
which PAK2 (7,27), LIMK2 (40), ARHGEF6 (41), CFL2,
PIK3R3 (42), PLAU (19) and ANXA2 (43) are regulated
by direct interaction of miR-23b with their 30UTRs
(Figure 6 and Supplementary Figure S4). Moreover, in
contrast to the other genes, luciferase levels of PAK2
30UTR did not increase after the miR-23b sponge trans-
fection. This suggests that the regulation exerted by miR-
23b on PAK2, binding to the analyzed site, makes a minor
contribution to the regulation of PAK2, indicating that
other mechanisms, indirectly mediated by miR-23b,
maybe involved. Interestingly, miR-23b over-expression
dramatically reduced, and conversely its inhibition
increased, lamellipodia size, which may explain changes
in BC cell motility and invasiveness. Furthermore, miR-
23b expression also increased FA size and the phosphor-
ylation of MLC II, which regulates cell contractility.
Importantly, these data indicate the mechanism of
action of miR-23b in BC cells and demonstrate that its
downregulation induces tumor growth, regulates cell–cell
junctions and increases cell motility and invasion.
Replacing miR-23b in BC patients may thus represent a
novel therapeutic strategy to prevent tumor progression
and metastatic spread.
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